The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
Prime Minister Narendra Modi will interact with doctors, paramedical staff and other frontline health workers of Varanasi on Friday via video conferencing. His office said Modi will review the working of various COVID hospitals in Varanasi, including the Pandit Rajan Mishra Covid Hospital, which was recently started through the joint efforts of the DRDO and the Indian Army. He will also review the working of non-Covid hospitals in the district. Modi will also discuss the ongoing efforts for tackling the second wave of COVID-19 in Varanasi and preparations for the future, the Prime Minister s Office said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
India Releases Its First Anti-COVID Drug (2-DG) Developed by DRDO
The drug arrests viral replication and inhibits multiplication and energy production inside the patient body
The efficacy of 2-DG was surprisingly good in improving patient recovery and curing the disease without the need for supplemental oxygen and prolonged hospitalization
India s most-awaited Anti-COVID drug 2-deoxy-D-glucose, developed by Defence Research and Development Organisation, is now out to serve as an adjunct therapy in moderate to severe SARS-CoV-2 infections.
During the first wave of COVID-19, DRDO researchers found that the molecule 2-deoxy-D-glucose effectively inhibits SARS-CoV-2 viral particles. Further, Phase-II clinical trials were conducted by the DRDO and Doctor Reddy s Laboratories, Hyderabad, from May to October 2020, to test its safety and efficacy.
Rajnath Singh Releases DRDO s Anti-Covid Drug 2-DG
The Drugs Controller General of India (DGCI) approved the 2-deoxy-D-glucose (2-DG) drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients earlier this month.
Outlook Web Bureau 17 May 2021, Last Updated at 12:40 pm File photo outlookindia.com 2021-05-17T12:40:17+05:30
Also read
Defence Minister Rajnath Singh and Health Minister Harsh Vardhan released the first batch of anti-Covid oral drug 2-DG, developed by the DRDO on Monday. In his brief remarks, Singh said the drug has brought a new ray of hope for the treatment of Covid-19 patients. This is a great example of the scientific prowess of our country, he said.
Union Defence Minister, Rajnath Singh (Photo/ANI)
Rajnath Singh to release first batch of DRDO s 2DG medicine for treating COVID-19 patients today ANI | Updated: May 17, 2021 04:49 IST
New Delhi [India], May 17 (ANI): The first batch of the 2-deoxy-D-glucose (2-DG) drug developed by the Defence Research and Development Organisation (DRDO) for treatment of Covid-19 will be released by Defence Minister Rajnath Singh on Monday.
Rajnath Singh s office tweeted, Raksha Mantri Rajnath Singh will release the first batch of anti-Covid drug 2DG via video conferencing facility tomorrow at 10.30 AM. The drug has been developed by DRDO s Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy s Laboratories.